Talecris Announces 2008 Application Cycle for Talents Research Grants, Presents 2007 Grant Awardees
Program grants $1 million to clinicians and scientists implementing novel studies with intravenous immunoglobulin therapies
RESEARCH TRIANGLE PARK, N.C. (May 14, 2008) — The Talecris New Trials Support program (Talents), sponsored by Talecris Biotherapeutics, Inc., is now accepting applications for the 2008 research grants cycle. The Talents program, entering its third year, aims to advance basic and clinical research addressing the use of intravenous immunoglobulin (IGIV) in immunological, hematological, and neurological indications. Totaling $1 million, the grants support either a one- or two-year research period and include funding for salary, overheads, and direct costs.
Application Process
Effective immediately, interested investigators are invited to submit a Letter of Intent (LOI) to the Talents Evaluation Committee, a committee comprised of Talecris scientists and external experts in immunology, neurology, and hematology. The deadline for submission of an LOI for the 2008 cycle is August 4, 2008. Upon LOI approval by the Evaluation Committee, investigators will receive a full application form to be completed by mid-October 2008. Selection of proposals for funding will be based on scientific merit, applicant qualifications, research environment, and consistency with the overall Talents program goals. Funding decisions and notification of award recipients will be made in late 2008 with funding beginning in 2009.
“When we announced this program in 2006, we did so with an aim to support the intellectual endeavors of the global IGIV research community,” said Larry Stern, Chairman and Chief Executive Officer, Talecris Biotherapeutics. “The scientific knowledge and insights gained from these funded studies are significant, and we continue to be impressed with the quality of the research teams and scientific proposals."
2007 Grant Recipients
Five clinicians who represent life science institutions from around the world received 2007 Talents grants. Grant monies will fund clinical and basic research studies ranging from the effects of IGIV on dendritic cell maturation, to the use of IGIV to protect kidney function from ischemia reperfusion, to a multi-year study investigating the effect of IGIV on complex regional pain syndrome (CRPS). The selected grant awardees represent three countries across Europe and North America: Germany, Canada, and the United States. Investigators and their academic institutions are listed below:
- Dr. Mark Ballow, Pediatric Associates, University of Buffalo, Buffalo, New York
- Dr. Franz Blaes, Justus-Liebig-University, Glaessen, Germany
- Dr. Jacob Prendergast, University Health Network, Toronto General Hospital, Toronto, Canada
- Dr. Hamid Rabb, Johns Hopkins University, Nephrology Division, Baltimore, Maryland
- Dr. Barbara Wasowska, Johns Hopkins University, Department of Pathology, Baltimore, Maryland
“As we enter our third year, Talents is attracting proposals from well-established scientists and clinicians working to implement novel approaches in IGIV therapy,” said Rene McRogers, Director of Scientific Relations and Communications and Talents Program Chair at Talecris Biotherapeutics. “We hope these innovative ideas will have a positive impact on this field and lead to insights that will help us further improve patient care.”
All information about the program, including how to apply, is available on the Talents Web site, www.talecristalents.com.
Contact:
Wendy Wilson
Tel.: 919.316.6316, Fax: 919.316.6673
E-mail: wendy.wilson@talecris.com
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.
Talecris, with revenues of approximately $1.2 billion in 2007, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 4,000 talented people worldwide.
To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com.
|
